Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (762)	12/16/1999 8:03:00 AM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

Thursday December 16, 7:46 am Eastern Time Elan starts Betabloc Phase I studies DUBLIN, Dec 16 (Reuters) - Irish pharmaceuticals group Elan Corp Plc (quote from Yahoo! UK & Ireland: ELA.L)(NYSE:ELN - news) said on Thursday it had started Phase I clinical studies of Betabloc, a therapeutic agent intended for the treatment of Alzheimer's disease. Elan said animal studies showed Betabloc prevented the buildup, and reduced the level, of established amyloid plaue, considered by many scientists to be one of the main causes of Alzheimer's disease. ``Based on these results, Elan has initiated clinical development to study the potential of this product candidate as a disease modifying agent,' Elan said in a statement. The studies, including up to 48 patients, will take a year to complete, Elan said. ``We are delighted that we have been able to move Betabloc so quickly into the clinic,' Donal Geaney, chairman and chief executive officer, said in a statement. ``As far as we know, Betabloc is the first potential agent to be evaluated in humans as an Alzheimer's disease plaque modifying agent,' Geaney said. biz.yahoo.com